Paul M. Watkins

Family Medicine
750 Morphy Ave
Fairhope, AL 36532

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Toward pharmacologic therapy for glioblastoma: Characterization of the very long-chain acyl-CoA synthetase 3 (ACSVL3) inhibitor Grassofermata.

Toward pharmacologic therapy for glioblastoma: Characterization of the very long-chain acyl-CoA synthetase 3 (ACSVL3) inhibitor Grassofermata.

Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026

Toward pharmacologic therapy for glioblastoma: Identifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3).

Toward pharmacologic therapy for glioblastoma: Identifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3).

Journal: bioRxiv : the preprint server for biology
Published: July 09, 2025

Role of ACSBG1 in Brain Lipid Metabolism and X-Linked Adrenoleukodystrophy Pathogenesis: Insights from a Knockout Mouse Model.

Role of ACSBG1 in Brain Lipid Metabolism and X-Linked Adrenoleukodystrophy Pathogenesis: Insights from a Knockout Mouse Model.

Journal: Cells
Published: August 26, 2024

Role of ACSBG1 in brain lipid metabolism and X-linked adrenoleukodystrophy pathogenesis: Insights from a knockout mouse model.

Role of ACSBG1 in brain lipid metabolism and X-linked adrenoleukodystrophy pathogenesis: Insights from a knockout mouse model.

Journal: bioRxiv : the preprint server for biology
Published: July 01, 2024

Depleting glioblastoma cells of very long-chain acyl-CoA synthetase 3 (ACSVL3) produces metabolic alterations in non-lipid pathways.

Depleting glioblastoma cells of very long-chain acyl-CoA synthetase 3 (ACSVL3) produces metabolic alterations in non-lipid pathways.

Journal: bioRxiv : the preprint server for biology
Published: October 03, 2023

VERY LONG-CHAIN ACYL-CoA SYNTHETASE-3 (ACSVL3) PROMOTES THE MALIGNANT GROWTH BEHAVIOR OF U87 GLIOMA CELLS VIA CHANGES IN CELL CYCLE WITHOUT AFFECTING APOPTOSIS.

VERY LONG-CHAIN ACYL-CoA SYNTHETASE-3 (ACSVL3) PROMOTES THE MALIGNANT GROWTH BEHAVIOR OF U87 GLIOMA CELLS VIA CHANGES IN CELL CYCLE WITHOUT AFFECTING APOPTOSIS.

Journal: bioRxiv : the preprint server for biology
Published: May 19, 2023

Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy.

Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: March 05, 2022

Very long-chain acyl-CoA synthetase 3 mediates onco-sphingolipid metabolism in malignant glioma.

Very long-chain acyl-CoA synthetase 3 mediates onco-sphingolipid metabolism in malignant glioma.

Journal: Medical research archives
Published: August 16, 2021

Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.

Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.

Journal: Journal of cellular biochemistry
Published: January 15, 2021

CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression.

CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression.

Journal: FEBS letters
Published: May 27, 2020

Addressing Medical Students' Negative Bias Toward Patients With Obesity Through Ethics Education.

Addressing Medical Students' Negative Bias Toward Patients With Obesity Through Ethics Education.

Journal: AMA journal of ethics
Published: October 23, 2018

Dendrimer-N-acetyl-L-cysteine modulates monophagocytic response in adrenoleukodystrophy.

Dendrimer-N-acetyl-L-cysteine modulates monophagocytic response in adrenoleukodystrophy.

Journal: Annals of neurology
Published: November 20, 2017
Showing 1-12 of 31

Last Updated: 09/26/2026